Generic · Tablet · Updated Nov 11, 2026
Tofacitinib 5 mg tablet price what pharmacies pay, and what you should
Is my price fair?
Check the price you were quoted
Type what the pharmacy asked for tofacitinib 5 mg tablet and see the markup over what they pay.
A benchmark from public data, not a price offer or medical advice. Prices vary by pharmacy, insurance and discount programs.
Tofacitinib 5 mg price history
What pharmacies pay for 30 tablets, weekly- Now
- $16.86
- 52-week low
- $16.86
- 52-week high
- $17.18
- A year ago
- -
Why the price changed
| Effective | Before | After | Change | Reason |
|---|---|---|---|---|
| Oct 21, 2026 | $0.5726 | $0.5619 | -1.9% | pharmacies' invoice prices changed (survey) |
Prices per tablet. Reasons are the ones the national survey gives: a survey rate change comes from pharmacies' own invoices; a published price change follows the maker's list price.
What people paid for tofacitinib 5 mg tablet
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Medicare negotiated price
Xeljanz was selected for Medicare price negotiation. Its negotiated price takes effect on January 1, 2028; the price itself is published by the end of November 2026.
What this means for patients
- The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
- What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
- Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
- If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Supply status: shortages & recalls
Every manufacturer and package code
8 companies sell tofacitinib 5 mg tablet under 8 package codes (NDCs). Pharmacies pay the same per tablet whichever maker they buy from - the national average is set for the generic as a group.
| Maker | Package codes | Per unit |
|---|---|---|
| Apotex Corp. | 60505-6263-6 | $0.5619 |
| Aurobindo Pharma Limited | 59651-459-60 | $0.5619 |
| Breckenridge Pharmaceutical, Inc. | 51991-329-06 | $0.5619 |
| Macleods Pharmaceuticals Limited | 33342-541-09 | $0.5619 |
| Micro Labs Limited | 42571-268-60 | $0.5619 |
| Novadoz Pharmaceuticals LLC | 72205-139-60 | $0.5619 |
| Somerset Therapeutics, LLC | 70069-841-01 | $0.5619 |
| Zydus Pharmaceuticals USA Inc. | 70710-1243-6 | $0.5619 |
All 8 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
The brand costs 131x more
Make sure your prescription is filled with the generic unless your prescriber wrote "brand medically necessary".
Questions to ask your pharmacist
- "Am I being charged for the generic or the brand?" The brand costs pharmacies up to $2,213.15 for the same amount.
- "What is your cash price, without insurance?" For low-cost generics it can be less than a copay.
- "Is a 90-day supply cheaper per tablet?" Dispensing fees are charged per fill, so fewer fills often cost less.
- "Do you match other pharmacies or accept discount cards?" Many do, if you ask.
These are questions, not advice. Never change how you take a medicine without talking to your prescriber or pharmacist.
Other tofacitinib strengths and forms
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 11 mg (24 hr) extended-release tablet | $2.09 | $62.63 / 30 tablets | ||
| 1 mg/mL oral solution | Not priced this week | |||
Official label & what changed
These highlights do not include all the information needed to use TOFACITINIB EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for TOFACITINIB EXTENDED-RELEASE TABLETS. TOFACITINIB extended-release tablets, for oral use Initial U.S. Approval: 2012
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS
SERIOUS INFECTIONS
Patients treated with tofacitinib extended-release tablets are at increased risk for developing serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB), that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Reported infections included:
Active TB, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent TB before tofacitinib extended-release tablets use and during therapy. Treatment for latent infection should be initiated prior to tofacitinib extended-release tablets use.
Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.
The risks and benefits of tofacitinib extended-release tablets treatment should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after tofacitinib extended-release tablets treatment, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. If a serious infection develops, interrupt tofacitinib extended-release tablets until the infection is controlled [see Warnings and Precautions (5.1)].
MORTALITY
In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular (CV) risk factor comparing XELJANZ tablets 5 mg or 10 mg twice a day to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden CV death, was observed with XELJANZ tablets 5 mg or 10 mg twice a day [see Warnings and Precautions (5.2)]. XELJANZ 10 mg twice daily and tofacitinib extended-release tablets 22 mg once daily dosages are not recommended for the treatment of RA, psoriatic arthritis (PsA), or ankylosing spondylitis (AS) [see Dosage and Administration (2.3)].
MALIGNANCIES
Malignancies, including lymphomas and solid tumors, have occurred in patients treated with XELJANZ and other Janus kinase inhibitors used to treat inflammatory conditions. In RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with XELJANZ tablets 5 mg or 10 mg twice a day compared with TNF blockers [see Warnings and Precautions (5.3)].
Lymphomas and lung cancers were observed at a higher rate in patients treated with XELJANZ tablets 5 mg or 10 mg twice a day in RA patients compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.
MAJOR ADVERSE CARDIOVASCULAR EVENTS
RA patients 50 years of age and older with at least one cardiovascular risk factor, treated with XELJANZ tablets 5 mg or 10 mg twice daily, had a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke), compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue tofacitinib extended-release tablets in patients that have experienced a myocardial infarction or stroke [see Warnings and Precautions (5.4)].
THROMBOSIS
Thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis have occurred in patients treated with XELJANZ and other Janus kinase inhibitors used to treat inflammatory conditions. Many of these events were serious and some resulted in death. RA patients 50 years of age and older with at least one cardiovascular risk factor treated with XELJANZ tablets 5 mg or 10 mg twice daily compared to TNF blockers had an observed increase in incidence of these events. Avoid tofacitinib extended-release tablets in patients at risk. Discontinue tofacitinib extended-release tablets and promptly evaluate patients with symptoms of thrombosis [see Warnings and Precautions (5.5)].
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR
EVENTS, and THROMBOSIS
See full prescribing information for complete boxed warning.
Increased risk of serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB), leading to hospitalization or death. Interrupt tofacitinib extended-release tablets treatment if serious infection occurs until the infection is controlled. Test for latent TB before and during therapy; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative latent TB test. (5.1)
Higher rate of all-cause mortality, including sudden cardiovascular (CV) death with XELJANZ vs. TNF blockers in rheumatoid arthritis (RA) patients. (5.2)
Malignancies have occurred in patients treated with XELJANZ. Higher rate of lymphomas and lung cancers with XELJANZ vs. TNF blockers in RA patients. (5.3)
Higher rate of major adverse CV events (defined as CV death, myocardial infarction, and stroke) with XELJANZ vs. TNF blockers in RA patients. (5.4)
Thrombosis has occurred in patients treated with XELJANZ. Increased incidence of pulmonary embolism, venous and arterial thrombosis with XELJANZ vs. TNF blockers in RA patients. (5.5)
Recent major changes (as listed on the label)
Boxed Warning | 10/2025 |
Indications and Usage, Psoriatic Arthritis (1.2) | 10/2025 |
Warnings and Precautions, Serious Infections (5.1) | 03/2026 |
Warnings and Precautions, Hypoglycemia in Patients with Diabetes (5.8) | 6/2026 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about tofacitinib 5 mg tablet
How much does tofacitinib 5 mg tablet cost without insurance?
Pharmacies pay about $16.86 for 30 tablets ($0.5619 per tablet) as of November 11, 2026. A fair cash price is about $29.89: that cost plus a 15% margin and a $10.50 dispensing fee. Online cost-plus pharmacies charge around $29.39 including shipping.
Is my price for tofacitinib 5 mg tablet fair?
Compare it with the fair cash price of $29.89 for 30 tablets. Up to about $37.36 is fair; above $59.78 is high, and worth asking the pharmacy for its cash price or trying another pharmacy. Check your quote.
Is tofacitinib 5 mg tablet getting more expensive?
Over the last four weeks the price pharmacies pay fell 1.9%. See the 52-week chart.
What is the brand name of tofacitinib 5 mg tablet?
Xeljanz 5 mg tablet. The brand has the same active ingredient but costs pharmacies more.
Who makes tofacitinib 5 mg tablet?
8 companies: Apotex Corp., Aurobindo Pharma Limited, Breckenridge Pharmaceutical, Inc., Macleods Pharmaceuticals Limited, Micro Labs Limited, Novadoz Pharmaceuticals LLC, Somerset Therapeutics, LLC, Zydus Pharmaceuticals USA Inc.. See every package code.
Is tofacitinib in shortage?
No shortage is reported right now. We check every day.
Has tofacitinib been recalled?
No recalls are on record.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about tofacitinib 5 mg tablet
No comments yet. Questions, tips, what worked for you - start the conversation.